Healthcare Web Wire

Blog

  • Oral Factor Xa Inhibitors Market Trends, Challenges, and Growth Opportunitie

    Oral Factor Xa Inhibitors Market Companies, Segmental Analysis and Growth

    The global oral factor Xa inhibitors market was estimated at US$ 21.5 billion in 2023 and is projected to grow to US$ 41.24 billion by 2034, rising at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2034. The demand for oral factor Xa inhibitors is increasing due to their ease of use. The inhibitors are easy to store and consume and do not require any professionals to administer them.

    Oral Factor Xa Inhibitors Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5291

    Oral Factor Xa Inhibitors Market Trends

    In May 2023, the World Health Organization (WHO) set an ambitious target to reduce premature deaths from non-communicable diseases by 25% by 2025. To achieve this, a major focus must be on combating cardiovascular diseases, particularly through the use of direct oral anticoagulants (DOACs). Since January 2022, more than 460,000 people have started using anticoagulant medications, and over 24 million prescriptions have been issued. This has helped prevent an estimated 17,000 strokes and 4,000 deaths. Atrial fibrillation (AF), which affects approximately 1.5 million people in England alone, is responsible for one in five strokes.

    In January 2022, the NHS revised its guidelines to recommend edoxaban as the preferred option for prescribers due to its cost-effectiveness compared to other approved DOACs. This decision saved the NHS more than £100 million in medical costs.

    Increasing Stroke Cases Drive the Demand for Anticoagulants

    Globally, over 100 million people have experienced a stroke. More than 60% of strokes occur in individuals under the age of 70, with 16% affecting those under 50. By 2030, the economic impact of stroke is expected to reach a staggering US$1 trillion, representing about 0.66% of global GDP. When the right anticoagulants are used, the risk of ischemic stroke can be reduced. Identifying the most effective combination of antiplatelet and anticoagulant medications for stroke prevention remains a key medical goal. Oral direct factor Xa inhibitors have been approved by the U.S. FDA for stroke prevention.

    High Costs Remain a Barrier for the Oral Factor Xa Inhibitors Market

    Despite their benefits, the high cost of factor Xa inhibitors poses a significant challenge. The price for a 28-day treatment with factor Xa inhibitors is approximately US$3,784.20 per patient. Including follow-up costs, the total expense for a 28-day treatment course can reach as much as US$77,125.60. The average annual cost per patient for factor Xa inhibitor therapy is US$4,370.93. In the U.S., this cost disparity is expected to increase, potentially totaling more than US$14.1 billion annually by 2040. Factor Xa inhibitor thromboprophylaxis can be up to 1,980.6% more expensive than an aspirin regimen, due to the high main treatment costs, variable management fees, and follow-up care.

    Recent Developments

    • In August 2024, the “maximum fair price” (MFP) for ELIQUIS® (apixaban), which was chosen during the first round of government price setting under the Inflation Reduction Act (IRA), was announced by the U.S. Department of Health and Human Services, according to Pfizer Inc. As of January 1, 2026, Medicare will cover $231.00 for a 30-day equivalent supply of ELIQUIS, the medication’s necessary MFP.
    • In February 2024, in countries where the CE mark is recognized, Roche announced the introduction of three new coagulation tests for the oral Factor Xa inhibitors: rivaroxaban, edoxaban, and apixaban.

    Top Companies in the Oral Factor Xa Inhibitors Market

    • Hansoh Pharma
    • Pfizer
    • Kelun Pharmaceutical
    • Zhejiang Hisun Pharmaceutical
    • BrightGene
    • GlaxoSmithKline
    • Accord Healthcare
    • Qilu Pharmaceutical
    • Dr. Reddy’s Laboratories
    • Chia Tai Tianqing Pharmaceutical
    • Lupin
    • HEC Pharma
    • Cspc Ouyi Pharmaceutical
    • Nanjing King-Friend Biochemical Pharmaceutical
    • Jiangsu Hengrui Pharmaceuticals
    • Bristol Myers Squibb
    • Eugia Pharma
    • Apotex
    • Viatris
    • Janssen Pharmaceuticals
    • Shanghai Huilun Pharmaceutical
    • Bayer
    • Daiichi Sankyo
    • Zydus

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/oral-factor-xa-inhibitors-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5291

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Blood Products Market Growth Impact of Cancer Prevalence and Advancements in Treatment

    Competitive Landscape and Key Players in the Blood Product Market

    The global blood product market was estimated at US$ 36.52 billion in 2023 and is projected to grow to US$ 59.89 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2034. The demand for blood and blood products is high due to their usage during surgeries, emergency situations, blood-related health issues, and many more health problems.

    Blood Product Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5292

    • In October 2024, the $5 million AUD grant that Australia’s National Health and Medical Research Council (NHMRC) recently gave to the Blood Synergy research program is the first time that this funding has been utilized to expand an already-existing project.
    • In September 2024, in addition to the more than $15 million in investment that the U.S. Department of Defense has already provided, Safi Biotherapeutics, the pioneer in the creation of manufactured red blood cells (mRBCs) as a substitute for donor blood transfusions, announced a $5 million seed round headed by J2 Ventures.
    • In May 2023, with $50 million in hand from the innovative York Blood Center, NYBC Ventures was announced as one of the first venture firms to concentrate only on developing innovative blood and cell-based medicines.
    • 40% of the 118.5 million blood donations that are collected worldwide take place in high-income nations, which are home to sixteen percent of the world’s population. A total of 106 million contributions have been reported by 13,300 blood clinics throughout 169 countries.

    Blood Product Market is Growing Due to Cancer

    • Higher Demand from Cancer Treatments: Cancer treatments like chemotherapy and radiation often lead to a drop in blood cell production, making patients need more blood products such as platelets, red blood cells, and plasma. This creates a continuous demand for blood transfusions.
    • Stem Cell Therapies: Blood products, including stem cells, are becoming essential in cancer care, helping patients recover after treatments and supporting the regeneration of their immune systems.
    • Aging Population: As the global population ages, more people are being diagnosed with cancer. Older adults are more prone to cancer and its related complications, which further increases the need for blood products.
    • Innovations in Blood Products: New developments in blood storage and transfusion methods, along with alternatives like blood substitutes, are making it easier to provide these life-saving treatments, which is also fueling the market’s growth.
    • Better Cancer Survival Rates: Thanks to improved cancer treatments, survival rates are higher, but many cancer survivors still need ongoing support from blood products as part of their recovery.

    Recent Developments

    • In April 2024, the BD Vacutainer® UltraTouchTM Push Button Blood Collection Set was recently introduced in India by BD (Becton, Dickinson, and Company) with the goal of reducing patient pain and suffering and facilitating single-prick success during the blood collection procedure.
    • In February 2024, patients with sickle cell disease in England will soon have access to better care nearer to their homes thanks to an announced £1.5 million investment in 25 red blood cell exchange machines.

    Top Companies in the Blood Product Market

    • KM Biologics
    • Nanyue Bio
    • Nordisk
    • Weiguang Bio
    • Yuanda Shuyang
    • Boya Bio
    • F. Hoffmann-La Roche Ltd.
    • Shuanglin Bio
    • Bio-Rad Laboratories Inc.
    • Tiantan Bio
    • Hualan Bio
    • CBPO
    • LFB Group
    • Merck & Co, Inc.
    • RAAS
    • Biotest
    • Octapharma
    • Haemonetics Corporation
    • Grifols
    • Kedrion
    • CSL
    • Ortho Clinical Diagnostics
    • Takeda
    • BPL

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/blood-product-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5292

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Factor Xa Inhibitors Market Regional Growth, Key Drivers and Future Outlook

    Factor Xa Inhibitors Market Size, Segments and Companies

    The global factor Xa inhibitors market was estimated at US$ 22.1 billion in 2023 and is projected to grow to US$ 41.52 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2034. The growing prevalence of various heart-related health issues is driving the market.

    Factor Xa Inhibitors Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5285

    North America Leads the Charge

    In 2023, North America emerged as the dominant region in the Factor Xa inhibitors market, driven by its advanced healthcare infrastructure, substantial government support, increasing pharmaceutical investments, and the proactive roles played by major industry leaders. The United States and Canada are pivotal to this market’s growth, especially with the rising prevalence of stroke, a condition closely associated with atrial fibrillation (AF).

    Stroke remains one of the leading causes of mortality in the U.S., with an estimated 795,000 individuals experiencing a stroke annually, leading to a stroke-related death every 3 minutes. Atrial fibrillation, the primary cause of these strokes, underscores the importance of Factor Xa inhibitors as a key therapeutic approach to reduce stroke risk. The market is further supported by consistent advancements in medical treatments and innovations within the pharmaceutical sector.

    Asia Pacific: The Fastest-Growing Market

    On the other side of the world, Asia Pacific is expected to witness the fastest growth in the Factor Xa inhibitors market during the forecast period. With its vast population, rapidly expanding healthcare sector, and increasing cardiovascular disease (CVD) prevalence, the region is experiencing a surge in demand for these innovative treatments. Countries like China and India are key players, with their large consumer bases and growing healthcare investments.

    India, in particular, has seen an alarming rise in stroke-related mortality, with one person dying from a stroke every four minutes. The nation’s high stroke incidence and mortality rates underscore the urgent need for effective treatments like Factor Xa inhibitors. Recent regulatory approvals, such as AstraZeneca’s Andexanet Alfa in January 2024, highlight the ongoing progress in making these therapies more accessible in the region.

    Oral Medications Lead the Market

    In terms of product type, oral Factor Xa inhibitors have proven to be the most popular, capturing the largest share of the market in 2023. Oral drugs offer ease of administration, improved patient compliance, and cost-effectiveness, which make them a preferred option for managing conditions like atrial fibrillation. The drugs are typically absorbed in the small intestine, and their pharmacokinetic and pharmacodynamic properties play a key role in optimizing patient outcomes.

    Atrial Fibrillation: A Key Application

    Atrial fibrillation remains one of the most significant applications for Factor Xa inhibitors, holding a substantial share of the market. This heart condition is the leading cause of stroke, and anticoagulant therapies like Factor Xa inhibitors significantly reduce the risk of stroke and other complications. Projections indicate that by 2050, nearly 16 million Americans will suffer from AF, further highlighting the importance of these treatments in preventing adverse health outcomes.

    As the market for Factor Xa inhibitors continues to expand, both North America and Asia Pacific are set to play crucial roles in shaping its future, offering innovative solutions to combat cardiovascular diseases and improve patient quality of life.

    Top Companies in the Factor Xa Inhibitors Market

    • Pfizer
    • Hansoh Pharma
    • Daiichi Sankyo
    • Bayer
    • Shanghai Huilun Pharmaceutical
    • Viatris
    • Dr. Reddy’s Laboratories
    • GlaxoSmithKline
    • Janssen Pharmaceuticals
    • Eugia Pharma
    • Chia Tai Tianqing Pharmaceutical
    • Accord Healthcare
    • Bristol Myers Squibb
    • Apotex, Zydus
    • Lupin
    • Nanjing King-Friend Biochemical Pharmaceutical
    • HEC Pharma
    • Jiangsu Hengrui Pharmaceuticals
    • Cspc Ouyi Pharmaceutical
    • Qilu Pharmaceutical
    • BrightGene
    • Zhejiang Hisun Pharmaceutical
    • Kelun Pharmaceutical

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/insights/factor-xa-inhibitors-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5285

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Blood Plasma Fractionation Market Size, Trends, and Key Players (2023 – 2034)

    Blood Plasma Fractionation Market Size, Shares and Trends

    The blood plasma fractionation market was estimated at US$ 30.93 billion in 2023 and is projected to grow to US$ 74.74 billion by 2034, rising at a compound annual growth rate (CAGR) of 8.35% from 2024 to 2034. The rising incidences of immunological disorders and the prevalence of rare chronic disorders, increasing awareness about blood donations, and growing research and development drive the market.

    Blood Plasma Fractionation Market Revenue 2023 - 2034 (USD Billion)

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5286

    Blood Plasma Fractionation Market Isolating Therapeutic Proteins

    Blood plasma, the liquid portion of blood that makes up about 55% of its total volume, is essential in medical treatments. Plasma fractionation is the process of separating its various components using specialized techniques. These components include coagulation factors like factor VIII, factor IX, prothrombin complex, Von Willebrand factor, fibrinogen, immunoglobulins, protease inhibitors, anticoagulants, and albumin. These plasma-derived products are critical in treating life-threatening conditions such as trauma, congenital disorders, immunologic diseases, and infections.

    The increasing prevalence of immunological disorders, trauma, and blood disorders has led to a higher demand for blood plasma. For instance, albumin is vital in treating trauma, immunoglobulins are used for immunologic conditions, coagulation factors are essential in managing bleeding disorders like hemophilia, and protease inhibitors are used for treating emphysema. Additionally, growing blood donations and increasing awareness of plasma-based therapies are further driving market growth.

    Blood Plasma Fractionation Market Trends

    Several recent developments highlight the growth of the blood plasma fractionation market:

    • In August 2024, Ma’ruf Amin, the Vice President of Indonesia, urged the Indonesian Red Cross (PMI) and other stakeholders to develop a local plasma fractionation program to reduce the dependency on imported plasma-derived products, ensuring more sustainable access to safe and reliable blood products in Indonesia.
    • In December 2023, PlasmaGen Biosciences secured Rs 225 crore from UK-based Artian Investments to expand internationally, develop new products, and fund its operational needs.
    • In March 2023, CSL opened a new $470 million plasma fractionation facility, which significantly increased its capacity to convert donated plasma into life-saving medicines.

    Opportunities in the Blood Plasma Fractionation Market

    The rising demand for blood plasma products has spurred innovation in the field, leading to improvements in patient care and treatment outcomes. Researchers are exploring new fractionation techniques to isolate plasma components more efficiently and investigating the therapeutic potential of plasma products for treating various disorders. In low- and middle-income countries, where large-scale plasma donations may be scarce, smaller-scale fractionation methods are gaining traction. For example, ethanol is traditionally used as a precipitant in fractionation, but efforts to remove ethanol are helping to streamline small-scale processes using single-use equipment for quick deployment. Additionally, continuous manufacturing techniques are being explored to maintain efficiency and throughput without requiring large-scale facilities. Automation is also on the rise in plasma fractionation, helping to improve processes like plasma harvesting and cleaning.

    Challenges in the Blood Plasma Fractionation Market

    One of the main challenges facing the blood plasma fractionation market is the high initial investment required for equipment and infrastructure. Large-scale fractionation facilities and advanced technologies can be expensive, with single-use filtration costing up to $500 per gram, while plasma products can be priced as high as $150,000 per gram. This price disparity can make it difficult for small-scale manufacturers to afford the necessary equipment. Another significant hurdle is the need for a continuous, reliable supply of large volumes of plasma to meet growing demand, which remains a challenge in many regions.

    Recent Developments in the Blood Plasma Fractionation Market

    • In February 2024, GC Biopharma became the first Korean company to get regulatory approval for a blood plasma product, Alyglo, for marketing in the US market.
    • In November 2023, Grifols announced that it received approval from the US FDA for its new immunoglobulin purification and filling facility for producing Gamunex-C at its Clayton manufacturing campus. The company manufactures an additional 16 million grams of the therapy annually, with a total global capacity of 60 million grams.

    Top Companies in the Blood Plasma Fractionation Market

    • ADMA Biologics, Inc.
    • Baxter International, Inc.
    • Bio Products Laboratory
    • Biotest AG
    • CSL
    • GC Biopharma
    • Grifols, S.A.
    • Kedrion Biopharma
    • LFB S.A.
    • OctaPharma
    • PlasmaGen Biosciences
    • Sanquin
    • SK Plasma
    • Takeda Pharmaceutical Co. Ltd.

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/blood-plasma-fractionation-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5286

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • DOACs Market Trends, Opportunities and Regional Growth

    Direct Oral Anticoagulants (DOACs) Market Companies

    The global direct oral anticoagulants (DOACs) market was estimated at US$ 43.9 billion in 2023 and is projected to grow to US$ 102.36 billion by 2034, rising at a compound annual growth rate (CAGR) of 8% from 2024 to 2034. DOACs are in high demand due to their use as anticoagulation in various cardiovascular diseases.

    Direct Oral Anticoagulants (DOACs) Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5287

    Market Overview

    Direct Oral Anticoagulants (DOACs) have quickly become a preferred alternative to the traditional anticoagulant treatment involving vitamin K antagonists. These medications are used to prevent and treat various cardiovascular disorders and have become particularly popular in managing thromboembolic conditions. DOACs offer patients and healthcare providers safer, more convenient, and effective treatment options. However, as their use increases, clinicians face more complex decisions regarding the appropriate drugs, treatment duration, and specific patient considerations.

    DOACs Market Trends

    In May 2023, VarmX, a biotech company focused on developing new ways to reverse anticoagulation, raised an additional €30 million in a Series B2 funding round.
    In November 2022, the adoption of anticoagulants increased significantly, with around 460,000 new patients starting treatment since January 2022. This led to over 24 million prescriptions being written, helping prevent an estimated 17,000 strokes and 4,000 deaths.

    Market Opportunity: Rising Cardiovascular Disease Cases

    Cardiovascular Diseases (CVDs) Death Rates (2019 vs. 2030)

    Despite advances in prevention and treatment, CVDs remain a leading cause of death worldwide. In the U.S., non-communicable diseases (NCDs), especially CVDs, place a heavy burden on the healthcare system. The CDC reports that NCDs cost the U.S. economy over $216 billion in healthcare expenses and result in $147 billion in lost productivity due to workplace absenteeism. The rising incidence of thrombotic events in CVDs, which can be mitigated with anticoagulants, is driving the demand for DOACs. These drugs are widely used for stroke prevention in atrial fibrillation, treating acute coronary syndrome, and preventing future cardiovascular events.

    Market Challenge: Side Effects of DOACs

    While DOACs offer significant benefits, they also come with potential side effects. Like all medications, DOACs can cause adverse reactions in some patients, with bleeding being one of the most serious risks. Major bleeding events are a particular concern, and managing these risks remains a challenge for healthcare providers.

    Regional Insights

    North America Leads the DOACs Market

    In 2023, North America dominated the DOACs market, driven by advanced healthcare infrastructure, government support, and substantial investments from pharmaceutical companies. The U.S. and Canada are the key contributors to this market growth.
    The U.S. alone has a high incidence of cardiovascular diseases, with a growing emphasis on tackling these health challenges. By 2050, the cost of healthcare for cardiovascular conditions in the U.S. is expected to more than triple, significantly impacting the economy and healthcare spending.

    Asia Pacific: Fastest Growing Region

    Asia Pacific is expected to experience the fastest market growth during the forecast period. The region’s large population offers a massive consumer base and skilled workforce, driving the growth of the DOACs market. Key factors include increased healthcare investments, rising innovation, and a growing prevalence of CVDs in countries like China and India.
    China currently has over 330 million CVD patients, with a significant portion suffering from hypertension, coronary heart disease, heart failure, and atrial fibrillation. Similarly, in India, a major heart health awareness campaign launched in 2023 aims to treat 75 million people with diabetes and hypertension by 2025, marking a significant step in addressing CVD risks.

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field –  https://www.towardshealthcare.com/table-of-content/direct-oral-anticoagulants-doacs-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5287

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Medical Device Gaskets & Seals Market Trends, Growth, and Innovations (2024 – 2032)

    The medical device gaskets & seals market was estimated at US$ 0.92 billion in 2023 and is projected to grow to US$ 1.57 billion by 2034, rising at a compound annual growth rate (CAGR) of 5% from 2024 to 2034. Latest innovations in medical devices, advanced healthcare infrastructure, and increasing investments drive the market.

    Medical Device Gaskets and Seals Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5288

    Medical Device Gaskets & Seals Market: Connecting Edges

    Medical device gaskets and seals play a vital role in protecting medical devices against fluids, contaminants, electromagnetic interference, and dust. They should have sufficient mechanical strength, chemical resistance, and sanitary sealing capabilities and resist heat, flame, electrostatic discharge, and electrical conductivity. The materials used for medical device gaskets & seals should meet regulatory and functional requirements. The ideal seal in medical devices would be one that can maintain its integrity under varying pressure and temperature conditions.

    The gaskets and seals are commonly used in medical pumps, IV components, implant materials, feeding devices, lab equipment, and temperature control devices. The increasing demand for medical devices due to growing healthcare infrastructure and rising chronic disorders boosts the market.  The market is also driven by the latest innovations in medical devices and the increasing number of surgeries.

    Segmental Insights

    In 2023, the rubber segment led the medical device gaskets and seals market. Medical-grade rubber is commonly used to make seals and gaskets that can withstand various process media. It offers heat resistance, electrical conductivity, and protection against electrostatic discharge. Additionally, rubber is versatile, cost-effective, and easy to sterilize, making it ideal for medical devices. It is also biocompatible, durable, flexible, and resilient.

    The silicone segment is expected to experience significant growth in the medical device gaskets and seals market during the forecast period. Silicone is a popular choice for making gaskets and seals due to its resistance to bacterial growth, moisture, and heat. It is non-toxic, biologically inert, and biocompatible, which makes it suitable for medical devices in direct contact with human tissues.

    In terms of application, diagnostic equipment dominated the global medical device gaskets and seals market in 2023. The rising prevalence of chronic diseases, the increasing demand for early disease detection, and the growth of the medical diagnostic device industry are driving this segment. Diagnostic equipment often requires specialty foam gaskets for displays and dust filters, with materials like silicone and neoprene commonly used for these gaskets and seals.

    The implants and catheters segment is expected to capture a larger share of the market in the coming years. The growing number of surgeries and the increasing prevalence of chronic diseases are contributing to this growth. Implants and catheters, widely used in cardiac and neurostimulation devices, stents, and medical valves, often require biocompatible, high-quality gaskets and seals due to their direct contact with the body.

    Recent Developments in the Market

    In March 2024, Precision Polymer Engineering launched Perlast G77X, a perfluoroelastomer (FFKM) sealing material designed for high-temperature performance with exceptional low compression set. This material can be molded into O-rings and custom shapes.

    In December 2023, Lagercrantz’s International Division acquired DP Seals, a company specializing in high-quality, customized rubber seals, gaskets, and moldings.

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/medical-device-gaskets-and-seals-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5288

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Biomedical Refrigerator Market Key Trends, Growth Factors, and Future Prospects

    Biomedical Refrigerator Market Companies, Shares and Growth

    The biomedical refrigerator market was estimated at US$ 2.02 billion in 2023 and is projected to grow to US$ 3.64 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2034. The increasing demand for vaccines and antibiotics, rising demand for blood banks, and growing research & development activities like proteomics and genomics drive the market.

    Biomedical Refrigerator Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5281

    Biomedical Refrigerator Market: Ensuring the Safe Storage of Biologicals

    A biomedical refrigerator is a specialized cooling system designed to store temperature-sensitive biological materials, such as blood, vaccines, biological reagents, medications, and genetic materials like RNA and DNA. Unlike regular household refrigerators, these units offer precise temperature control, consistent cooling, and often come with dedicated compartments to organize different types of samples. They typically feature a microprocessor-based system that accurately monitors and controls the internal temperature using sensors like thermocouples, resistance temperature detectors (RTDs), and thermistors.

    Biomedical refrigerators are widely used in hospitals, blood banks, diagnostic centers, pharmacies, educational institutions, and research labs. The growing prevalence of chronic diseases, including viral infections, has spurred the demand for vaccines, which require cold storage to maintain their effectiveness. Additionally, certain antibiotics and biological therapies also need refrigeration. The increasing awareness around blood donation and the rise in blood-related disorders have further boosted the demand for biomedical refrigerators in blood banks. Furthermore, the expansion of research in proteomics and genomics has contributed to the growing need for these refrigerators to store critical biological samples like proteins, DNA, and RNA.

    Biomedical Refrigerator Market Trends

    In July 2024, the newly renovated Guba Community Hospital in Cebu City was unveiled, with funding from the Department of Health (DOH). As part of the renovation, the DOH also donated biomedical refrigerators to the hospital to safely store various biological samples.

    In February 2024, PHC Corporation of North America launched a new model of its PHCbi brand VIP ECO SMART ultra-low temperature freezers, designed for medical institutions, universities, and pharmaceutical companies. This new series aims to reduce power consumption while still offering reliable preservation capabilities.

    In August 2022, Azenta, Inc. acquired B Medical Systems, a global leader in medical refrigeration, including ultra-low freezers. This acquisition enhances Azenta’s cold chain solutions, providing more advanced options for the safe and traceable transportation of temperature-sensitive biological samples.

    Rising Demand for Cell and Gene Therapy: A Growing Opportunity for the Biomedical Refrigerator Market

    Cell and gene therapy products, including stem cells, cancer vaccines, RNA, DNA, and other biological therapies, require strict cold storage conditions. For example, stem cells need temperatures between -80°C and -196°C, while RNA and DNA must be stored at -70°C to -80°C. As the demand for these therapies increases, especially with more regulatory approvals, the need for biomedical refrigerators in research and clinical settings is growing. In 2023 alone, cell and gene therapy developers raised $3.5 billion across 65 deals, highlighting the sector’s rapid expansion. This growth in research and the number of clinical trials is fueling demand for biomedical refrigerators.

    High Upfront Costs: A Challenge for the Biomedical Refrigerator Market

    A significant challenge for the biomedical refrigerator market is the high upfront cost. New biomedical refrigerators typically range from $2,000 to $15,000, depending on the size, capacity, and features of the unit. Advanced models, such as those with ultra-low temperature capabilities or explosion-proof designs, can be even more expensive. This high cost can limit access to these units, especially for smaller businesses or institutions with tighter budgets.

    Top Companies in the Biomedical Refrigerator Market

    • Angelantoni Life Sciences
    • Arctiko
    • B Medical Systems
    • Biomedical Solutions, Inc.
    • Eppendorf AG
    • Haier Biomedical
    • NuAire
    • PHC Holdings Corporation
    • Philips Kirsch GmBH
    • SKSurgitech
    • Terumo Corporation
    • Vestfrost Solutions

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/biomedical-refrigerator-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5281

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Leuprorelin Drugs Market Size, Share, and Forecasts (2023 – 2034)

    Leuprorelin Drugs Market Size, Trends, and Innovations

    The global leuprorelin drugs market was valued at $2.60 billion in 2023 and is expected to grow to $4.78 billion by 2034, with a compound annual growth rate (CAGR) of 5.7% from 2024 to 2034. The increasing demand for leuprorelin drugs is driven by their effectiveness in treating a variety of hormone-related health conditions.

    Leuprorelin Drugs Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5282

    Market Overview Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist, is approved by the FDA for treating several conditions, including endometriosis, breast cancer, paraphilia, hypersexuality, central precocious puberty, and prostate cancer. The growing use of these drugs across such applications is fueling the market’s expansion. The rise in central precocious puberty, particularly among the newer generations, is linked to dietary changes, including hormone-injected foods such as eggs, milk, and poultry. Additionally, there has been a notable increase in transgender surgeries, with leuprorelin playing a key role in hormone treatment for male-to-female transgender individuals.

    Leuprorelin Drugs Market Trends In December 2023, Daewoong Pharmaceutical Co. Ltd. and Zydus Lifesciences Ltd. entered into a licensing agreement to jointly develop and market a generic form of leuprolide acetate for depot suspension. This drug is commonly used to treat conditions such as endometriosis, advanced prostate cancer, and uterine fibroids.

    In September 2023, Astellas Pharma Inc. announced that the European Medicines Agency (EMA) had approved the Type II version of its XTANDI® (enzalutamide) for hormone-sensitive prostate cancer patients who have not experienced metastasis.

    Growing Demand from Gender-Affirming Surgeries The rise in gender-affirming surgeries has significantly impacted the demand for leuprorelin drugs. These drugs are commonly used in hormone therapy, which is a key part of many gender-affirming treatments. Leuprorelin helps suppress the production of testosterone and estrogen, which is essential for these procedures. As the number of people seeking gender-affirming surgeries increases, the demand for leuprorelin drugs is expected to grow as well.

    For example, in the U.S., up to 78% of transgender or nonbinary individuals have a gender identity or expression that differs from the sex they were assigned at birth. Between 2019 and 2023, over 13,000 gender reassignment surgeries were performed on individuals aged 17.5 years or younger, with the youngest patient being just seven years old.

    Challenges Facing the Leuprorelin Drugs Market Despite its effectiveness, leuprorelin medications are associated with several side effects that could discourage some individuals from using them. These include potential exacerbation or onset of metabolic conditions such as diabetes, hyperglycemia (high blood sugar), hyperlipidemia, cirrhosis, or non-alcoholic fatty liver disease.

    Recent Developments

    • In November 2022, Leuprolide Acetate Injection Depot 22.5mg was introduced by Cipla Limited and its fully-owned subsidiary Cipla USA Inc. A New Drug Application (NDA) filed under the 505(b)(2) regulatory pathway served as the basis for the product’s approval by the US Food and Drug Administration (the “US FDA”).
    • In March 2022, CAMCEVITM (leuprolide) 42mg injectable emulsion was launched in the United States for the treatment of advanced prostate cancer in adults, according to Accord BioPharma, the U.S. specialty branch of Intas Pharmaceuticals, Ltd.

    Top Companies in the Leuprorelin Drugs Market

    • Takeda Pharmaceutical
    • Beijing Biote Pharmaceutical
    • Accord BioPharma
    • Sun Pharmaceutical
    • AbbVie
    • Cipla
    • Tolmar
    • Merck
    • Eugia Pharma
    • Foresee Pharmaceuticals
    • Livzon Pharmaceuticals

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/leuprorelin-drugs-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5282

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Nerve Repair Solutions Market Trends, Challenges, and Growth Opportunities

    The global nerve repair solutions, including conduits, wraps, protectors, caps, and connectors market was valued at US$ 255 million in 2023 and is projected to reach US$ 691.98 million by 2034, with a CAGR of 9.5%. This growth is largely driven by rising diabetes cases, a key factor in nerve damage requiring surgical repair.

    Nerve Conduits, Wraps, Protectors, Cap, Connectors Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5283

    Market Overview

    Nerve damage can occur in different manners. Depending on the way a nerve is damaged, different products can be used to repair it. For instance, conduits are pipes used to properly regulate nerves. Wraps are sheaths used for the protection and repair of partially damaged nerves. The coaptation location of severed nerves is relieved of stress by nerve connections. Assist coaptation in cable grafting, grafting, or direct repair. The coaptation location should be strengthened. Axonal regeneration of transected nerves is inhibited by nerve caps, which also isolate the site of nerve transection. Each of them has a different function and is in demand due to growing cases of diabetes. Diabetes slowly starts damaging nerves, and around 50% of diabetic patients deal with nerve damage and need nerve repair procedures at some point.

    Significant Funding for Innovation in Nerve Repair Technologies

    In October 2023, the National Institutes of Health (NIH) awarded BioCircuit Technologies, an Atlanta-based medical device company, a $1.9 million grant aimed at advancing the development and commercialization of Nerve Tape® — the first sutureless technology for repairing transected nerves. This funding, part of a broader goal of raising $2.4 million over three years, will support the final stages of product creation and market entry for this groundbreaking solution.

    In May 2023, TISSIUM secured €50 million in a Series D funding round, drawing support from both new and existing global investors. This investment aligns with TISSIUM’s first-in-human trials of its initial nerve repair product, COAPTIUM Connect, in Australia, alongside multiple regulatory processes that are currently underway.

    The Shift Toward Minimally Invasive Surgery in Nerve Repair

    Minimally invasive surgery is driving growth in the nerve repair market, particularly for conduits, wraps, protectors, caps, and connectors. These procedures, which involve minimal physical intrusion, offer significant benefits over traditional surgeries, including a lower risk of infection, faster recovery, shorter hospital stays, reduced postoperative pain, and lower costs. The increased use of robotic-assisted techniques further enhances the precision and success rates of these surgeries, making minimally invasive approaches increasingly popular.

    Market Challenge: High Costs in Nerve Repair Solutions

    The high costs associated with nerve repair products remain a notable challenge for market growth. Patients unable to afford these specialized products may turn to alternative therapies, reducing demand for nerve repair solutions. Additionally, limited reimbursement in certain healthcare systems can further restrict accessibility and adoption of these advanced repair products.

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/nerve-conduits-wraps-protectors-cap-connectors-market-sizing

    To own our research study instantly, Click here @https://www.towardshealthcare.com/price/5283

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

  • Clavulanic Acid Series API Market Size, Share, and Future Growth Analysis

    Clavulanic Acid API Market Growth Forecast and Key Trends

    In 2023, the clavulanic acid series API market was valued at approximately USD 385 million and is expected to reach USD 777.66 million by 2034, growing at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2034. This growth is driven by increasing cases of antibiotic-resistant bacterial infections and expanding research and development activities in the field.

    Clavulanic Acid Series API Market Revenue 2023 - 2034

    Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5284

    Clavulanic Acid Series API Market Trends

    In March 2024, the Central Drug Standard Control Organization (CDSCO) approved an update to the prescribing information for GSK’s fixed-dose combination, Amoxicillin Trihydrate. The new formulation includes Amoxicillin free acid (652.78 mg) with Potassium Clavulanate (61.48 mg, equivalent to 50.41 mg of Clavulanic acid) per 5 ml of reconstituted suspension.

    In September 2024, Kinvan, an Indian pharmaceutical company, began producing its first clavulanic acid formulation, Augmentin, targeting a range of bacterial infections. Kinvan has allocated INR 447.17 crores to establish a facility with a 300 metric ton annual production capacity for clavulanic acid, expected to be operational by the end of 2024.

    Expanding Research and Development: An Opportunity for Market Growth

    The importance of clavulanic acid in healthcare continues to grow as researchers explore its potential in combination therapies. Clavulanic acid is being studied for effectiveness in treating surgical site infections in pediatric appendectomies, dental infections, and infections from colorectal surgeries, among others. As of October 2024, 39 clinical trials involving clavulanic acid as an intervention are registered on ClinicalTrials.gov, with 32 currently recruiting and seven active but not recruiting. These trials explore clavulanic acid’s potential in managing conditions like cocaine use disorder, obstetric perineal tears, appendectomies, and aspiration in ICU patients. The rising demand for clavulanic acid, coupled with ongoing research into expanded applications, is expected to support the market’s growth.

    Regional Distribution of Current Clinical Trials

    Challenges in Production

    The production of clavulanic acid involves complex processes, primarily due to limited substrate availability. Clavulanic acid is derived from Streptomyces clavuligerus, which requires specific substrates that are often costly and scarce, causing production delays. For example, ATCC offers Streptomyces clavuligerus at around $420 per unit, making it an expensive starting material. Additionally, downstream processes like recovery and purification add to production challenges, impacting overall market growth.

    Top Companies in the Clavulanic Acid Series API Market

    • Apotex Inc.
    • Centrient Pharmaceuticals
    • CKD Bio Corporation
    • Fermic
    • Fidia Farmaceutici S.P.A.
    • GlaxoSmithKline
    • Hikma Pharmaceuticals
    • Lek Pharmaceuticals
    • Novopharm Ltd.
    • Rochem International, Inc.
    • Sandoz
    • Senova Technology Co. Ltd.
    • Shandong N.T. Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Wockhardt Ltd.
    • Zhuhai United Labs

    Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/clavulanic-acid-series-api-market-sizing

    To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5284

    You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

    About Us

    Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

    Visit Dental Specifics: https://www.towardsdental.com

    Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

    For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare